Condition: Ovarian Neoplasms · Carcinoma, Ovarian Epithelial · Neoplasm of Stomach · Sponsor: Sheba Medical Center
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will receive pembrolizumab and lenvatinib.
This description comes directly from the study's public registry record.
Ronnie Shapira, MD · +972-526666708 · Ronnie.Shapira@sheba.health.gov.il
Always discuss trial participation with your own doctor first.
| Sheba Medical center | Ramat Gan, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04519151